Long-acting pegylated human GH in children with GH deficiency: A single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics

Jean De Schepper, Michael Højby Rasmussen*, Zoran Gucev, Alon Eliakim, Tadej Battelino

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: GH replacement therapy currently requires daily injections, which may be inconvenient and distressing for young patients. This study determined the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single doses of a pegylated GH (NNC126-0083) developed for onceweekly administration, in children with GH deficiency (GHD). Design and methods: Thirty children (age ≥6 and ≤12 years, weight ≥16 kg) were randomised to NNC126-0083 or daily GH treatment. The subjects discontinued their daily GH treatment 7-9 days before receiving NNC126-0083 at 0.01, 0.02, 0.04 or 0.06 mg protein/kg (n=22) or seven once-daily doses of GH at 0.035 mg protein/kg (n=8). Results: NNC126-0083 was well tolerated, and no short-term safety or local tolerability issues were identified. After NNC126-0083 treatment, dose-dependent IGF1 increases were evident for maximum concentration (Cmax), but not area under the curve (AUC0-168 h). Mean values for IGF1 AUC0-168 h/168 h and Cmax were higher for GH than for NNC126-0083, although the difference was not statistically significant for cohort's 0.06 mg protein/kg. At 0.06 mg protein/kg, the resulting IGF1 response began subsiding at ∼3 days post-dose. Conclusion: Single doses of long-acting NNC126-0083 were safe and well tolerated in children with GHD. Increased IGF1 levels were observed in all NNC126-0083 dose groups; however, a satisfactory once-weekly IGF1 profile was not reached within the NNC126-0083 dose levels administered.

Original languageEnglish
Pages (from-to)401-409
Number of pages9
JournalEuropean Journal of Endocrinology
Volume165
Issue number3
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Dive into the research topics of 'Long-acting pegylated human GH in children with GH deficiency: A single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics'. Together they form a unique fingerprint.

Cite this